|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:activeIngredient
|
gptkb:sirolimus
|
|
gptkbp:approvedBy
|
gptkb:FDA
1999
|
|
gptkbp:ATCCode
|
L04AA10
|
|
gptkbp:CASNumber
|
53123-88-9
|
|
gptkbp:chemicalFormula
|
C51H79NO13
|
|
gptkbp:contraindication
|
hypersensitivity to sirolimus
|
|
gptkbp:drugClass
|
gptkb:immunosuppressant
|
|
gptkbp:eliminationHalfLife
|
62 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:form
|
gptkb:tablet
oral solution
|
|
gptkbp:indication
|
renal transplant rejection prophylaxis
|
|
gptkbp:interactsWith
|
gptkb:milk
gptkb:cyclosporine
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Pfizer
|
|
gptkbp:mechanismOfAction
|
gptkb:mTOR_inhibitor
|
|
gptkbp:metabolism
|
liver (CYP3A4-mediated)
|
|
gptkbp:otherName
|
gptkb:sirolimus
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
92%
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:anemia
hypertension
thrombocytopenia
hyperlipidemia
impaired wound healing
|
|
gptkbp:usedFor
|
prevention of organ transplant rejection
|
|
gptkbp:bfsParent
|
gptkb:Wyeth
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Rapamune
|